ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1 (glucose)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01514253
Recruitment Status : Unknown
Verified January 2012 by Shay Barak, The Baruch Padeh Medical Center, Poriya.
Recruitment status was:  Not yet recruiting
First Posted : January 23, 2012
Last Update Posted : January 23, 2012
Sponsor:
Information provided by (Responsible Party):
Shay Barak, The Baruch Padeh Medical Center, Poriya

Brief Summary:
Glucose has analgesic and calming effects in newborns. To date, it is not known whether the beneficial effects extend to care giving procedures that are performed after painful procedures. The investigators objective is to determine the effect of glucose 25% analgesia in comparison to Materna RTF Stage 1 for procedural pain on infant pain responses during a subsequent care giving procedure.

Condition or disease Intervention/treatment Phase
Infant, Newborn, Diseases Drug: Glucose 25% Dietary Supplement: Materna RTF Stage 1 Other: Water for Injection Not Applicable

Detailed Description:

During hospitalization, a neonate undergoes a number of necessary procedures that may be either painful or cause discomfort to the baby.

Pain experienced during the neonatal period is known to have long term effects on the baby.

The red-reflex test is a routine examination performed on a neonate after birth and once again before discharge from the hospital. The examination causes discomfort to the infant Glucose has analgesic and calming effects in newborns. To date, it is not known whether the beneficial effects extend to care giving procedures that are performed after painful procedures. The investigators objective is to determine the effect of glucose 25% analgesia in comparison to Materna RTF Stage 1 for procedural pain on infant pain responses during a subsequent care giving procedure.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Care Provider, Investigator)
Official Title: Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1
Study Start Date : February 2012
Estimated Primary Completion Date : May 2012
Estimated Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose

Arm Intervention/treatment
Experimental: glucose 25%
1 ml of glucose once
Drug: Glucose 25%
1 ml glucose 25%, once

Experimental: infant formula
Materna RTF stage 1
Dietary Supplement: Materna RTF Stage 1
1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
Other Name: Materna RTF Phase 1

Placebo Comparator: Water for Injection
1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
Other: Water for Injection
1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
Other Name: WFI




Primary Outcome Measures :
  1. less discomfort [ Time Frame: immediate, during examination (day 1) ]
    the infant will experience less pain during examination



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 16 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Full term above 37 weeks gestation.
  • Normal birth-weight, healthy infants
  • Males and Females
  • Whose parents have signed the informed consent form

Exclusion Criteria:

  • Premature born below 37 weeks
  • Chromosomal abnormalities or congenital malformation.
  • Suffering neurological imbalance
  • Inability of oral feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514253


Contacts
Contact: Shay Barak, MD 04-6652328 sbarak@poria.health.gov.il
Contact: Robyn Rubin, Coordinator 04-6652328 rrubin@poria.health.gov.il

Locations
Israel
NICU Department, The Baruch Padeh medical Center - Poriya Not yet recruiting
Tiberias, Israel
Contact: Shay Barak, MD    04-6652328    sbarak@poria.health.gov.il   
Sub-Investigator: Amir Kushnir, MD         
Principal Investigator: Shay Barak, MD         
Sub-Investigator: Elena Chulsky, MD         
Sub-Investigator: Tatiana Dolgunova, MD         
Sub-Investigator: Natali Nikolski, MD         
Sub-Investigator: Natali Shaykevich, MD         
Sub-Investigator: Orly Benor, RN,BSN.MsN         
Sub-Investigator: Gilat Yeganeh, LLB,LLM, RN         
Sub-Investigator: Maryanne Nabso, RN,MA         
Sub-Investigator: Sijal Hlehel, RN,MA         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Investigators
Principal Investigator: Shay Barak, MD The Baruch Pade Medical Center - Poriya
Study Director: Amir Kushnir, MD The Baruch Padeh Medical Center - Poria

Responsible Party: Shay Barak, Senior Neonatologist, Neonatal Intensive Care, The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier: NCT01514253     History of Changes
Other Study ID Numbers: SAOR 006.CTIL
First Posted: January 23, 2012    Key Record Dates
Last Update Posted: January 23, 2012
Last Verified: January 2012

Keywords provided by Shay Barak, The Baruch Padeh Medical Center, Poriya:
glucose
analgesic
newborns

Additional relevant MeSH terms:
Infant, Newborn, Diseases